Sanofi acknowledges regulatory challenges as it gains OTC rights to Eli Lilly & Co.’s Cialis, upping the ante in large pharma firms’ consumer health product arms race with its bid to be the first to market a nonprescription erectile dysfunction drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?